The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

CDDF Webinar – Application of Artificial Intelligence in Leukaemia Diagnostics: Implications for Clinical Trials and Cancer Drug Development


The Cancer Drug Development Forum held a live webinar regarding Application of Artificial Intelligence in Leukaemia Diagnostics: Implications for Clinical Trials and Cancer Drug Development on Thursday 15 October 2020 at 18:00 – 19:00 (CET) / 12:00 – 13:00 (EDT) / 9:00 – 10:00 (PDT). This live webinar comprised of a 30-minute lecture given by Prof. Torsten Haferlach (MLL Munich Leukemia Laboratory) followed by a 30-minute discussion session.


Leukaemia diagnostics depends on phenotypes and experienced personnel. Innovations such as artificial intelligence, machine learning and cloud computing offer fascinating options to increase diagnostic accuracy and improve therapeutic selection. This talk will demonstrate how these technologies are already being used in a routine, accredited workflow and how they may change future drug development for haematological malignancies.


  • Thursday 15 October 2020
  • 18:00 – 19:00 (CET) / 12:00 – 13:00 (EDT) / 9:00 – 10:00 (PDT)


Prof Dr Dr Torsten Haferlach, CEO, MLL Munich Leukemia Laboratory

Prof Dr Torsten Haferlach is one of the world’s leading experts in the field of leukaemia. Engaging in groundbreaking research, the development of new diagnostic tools and treatment options, he has always pushed the boundaries within his chosen field. He is currently introducing AI in routine workflows of leukaemia diagnostics.

With an MD in medicine, a PhD in Germanistics, and extensive experience in the leukaemia diagnostic field, Dr Haferlach spent the first part of his career as a medical doctor and haematologist at the University Clinics in Kiel and Göttingen and later at the University Clinic in Munich. Here, he acted as both the senior physician at the Department of Internal Medicine and the head of the laboratory for leukaemia diagnostics.

In 2005, he set up the Munich Leukaemia Laboratory ( with three colleagues from complementary disciplines. Today, the lab employs a team of 210 employees to process over 88,000 blood or bone marrow samples per year. His practice treats more than 4,500 patients, and he is a significant contributor to his field, publishing well over 570 articles in top-ranking, peer-reviewed medical journals since the laboratory’s inception.



The webinar is moderated by two CDDF Board Members:



  • 18:00 – 18:05 (CET): Introduction (CDDF)
  • 18:05 – 18:35 (CET): Lecture (Prof. Torsten Haferlach)
  • 18:35 – 19:00 (CET): Q&A / discussion session (moderated by Prof. Axel Glasmacher and Prof. Ruth Plummer, CDDF)


Meeting Materials


Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752
Tel: +32 2 880 62 70